CONTRIBUTION OF INTESTINAL CYP3A TO FIRST PASS METABOLISM OF MIDAZOLAM

肠道 CYP3A 对咪达唑仑首过代谢的贡献

• 批准号: 6117753
• 负责人: D CRAIG BRATER
• 金额: $ 1.7万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117753
• 关键词: clarithromycin; clinical research; cytochrome P450; drug metabolism; human subject; intravenous administration; midazolam; oral administration; pharmacokinetics

A goal of this study is to determine the contribution of intestinal cytochrome P450 3A to the observed first-pass metabolism of midazolam following oral administration using silmultaneous intravenous and oral administration of midazolam and a stable isotope (N-midazolam). A second goal of the study is to determine if clarithromycin inhibits the metabolism of midazolam following oral administration at the intestinal or hepatic level.

这项研究的目的是确定肠道的贡献， 细胞色素P450 3A与观察到的咪达唑仑首过代谢 在使用同时经皮静脉内和经口 给予咪达唑仑和稳定同位素（N-咪达唑仑）。 第二 研究的目的是确定克拉霉素是否抑制 咪达唑仑经口给药后在肠道或 肝水平